PITTSBURGH, Dec. 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Quinapril Tablets USP, 5 mg, 10 mg, 20 mg, and 40 mg. Quinapril Tablets are the generic version of Pfizer Pharmaceuticals' Accupril^® Tablets.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
12/23/2004
CONTACT: Media, Heather Bresch, or Investors, Kris King, both of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com